Intestinal Neoplasms  >>  Caprelsa (vandetanib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
NCT00454116 / 2006-005023-42: A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

Completed
2
106
US, Europe, RoW
Vandetanib, ZD6474, ZACTIMA™, FOLFIRI
Genzyme, a Sanofi Company
Colorectal Cancer
03/08
11/09
NCT00500292 / 2006-005022-23: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

Completed
2
109
Europe, RoW
Vandetanib, AZ6474, ZACTIMA™, SAR390530, FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
Genzyme, a Sanofi Company
Colorectal, Cancer
03/08
11/16

Download Options